Entrada Therapeutics to Present at Upcoming Investor Conferences
07 Febrero 2024 - 6:00AM
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage
biopharmaceutical company aiming to transform the lives of patients
by establishing intracellular Endosomal Escape Vehicle
(EEV™)-therapeutics as a new class of medicines, today announced it
will participate in the following two investor conferences:
Oppenheimer 34th
Annual Healthcare Life Sciences Conference Dipal
Doshi, Chief Executive Officer, will participate in a virtual
fireside chat on Wednesday, February 14, 2024, at 2:00 p.m. Eastern
Time.
TD Cowen 44th Annual
Health Care Conference Nathan Dowden, President and Chief
Operating Officer, will participate on the Orphan Bone &
Neuromuscular Diseases panel on Monday, March 4, 2024, at 9:10 a.m.
Eastern Time in Boston, MA.
Live webcasts will be available on the Investor Relations
section of the Company’s website at www.entradatx.com. Replays will
be available on the Entrada website for 90 days following the
events.
About Entrada Therapeutics Entrada Therapeutics
is a clinical-stage biopharmaceutical company aiming to transform
the lives of patients by establishing a new class of medicines,
Endosomal Escape Vehicle (EEV™)-therapeutics, to engage
intracellular targets that have long been considered inaccessible
and undruggable. The Company’s EEV therapeutics are designed to
enable the efficient intracellular delivery of a wide range of
therapeutics into a variety of organs and tissues, resulting in an
improved therapeutic index. Through its proprietary, highly
versatile and modular EEV platform, Entrada is building a robust
development portfolio of RNA-, antibody- and enzyme-based programs
for the potential treatment of neuromuscular, immunological, ocular
and metabolic diseases, among others. The Company’s lead
oligonucleotide programs include ENTR-601-44, ENTR-601-45 and
ENTR-601-50 for the potential treatment of people living with
Duchenne who are exon 44, 45 and 50 skipping amenable,
respectively, as well as our partnered candidate VX-670 for
myotonic dystrophy type 1.
For more information about Entrada, please visit our
website, www.entradatx.com, and follow us on LinkedIn.
Investor and Media ContactKarla MacDonaldChief
Corporate Affairs Officerkmacdonald@entradatx.com
Entrada Therapeutics (NASDAQ:TRDA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Entrada Therapeutics (NASDAQ:TRDA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024